Treatment of Multiple Sclerosis on Natalizumab with Positive JCV Antibody (Index > 0.9)

Patients with multiple sclerosis receiving natalizumab therapy who test positive for John Cunningham virus (JCV) antibody — particularly with an index above 0.9 — face an elevated risk that warrants a structured clinical decision about continuing or changing therapy.

Clinical scenario

Multiple sclerosis currently managed with natalizumab; JCV antibody test positive with an index above 0.9 while on therapy. This combination signals a materially increased risk profile that clinical guidelines address with specific guidance on therapy modification.

Treatment approach (partial summary)

The evidence-based approach centres on switching to a disease-modifying therapy that carries a lower risk of PML. The timing and choice of the alternative agent are addressed specifically in the full structured regimen.

Complete sequencing, agent selection criteria, and timing details are in the full protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1212/WNL.0000000000005347

Clinicians should discuss switching to a DMT with a lower PML risk with people with MS taking natalizumab who are or become JCV antibody–positive, especially with an index of above 0.9 while on therapy (Level B).

Physicians and people with MS choosing to switch from natalizumab to fingolimod should initiate treatment within 8–12 weeks after natalizumab discontinuation (for reasons other than pregnancy or pregnancy planning) to diminish the return of disease activity (Level B).

View source ↗